Idiopathic pulmonary fibrosis in Sweden: report from the first year of activity of the Swedish IPF-Registry

被引:39
作者
Ferrara, Giovanni [1 ,2 ,3 ]
Carlson, Lisa [1 ]
Palm, Andreas [4 ]
Einarsson, Jonas [5 ,6 ]
Olivesten, Cecilia [7 ]
Skold, Magnus [1 ,2 ,3 ]
机构
[1] Karolinska Univ Hosp, Dept Resp Med & Allergy, SE-17176 Stockholm, Sweden
[2] Dept Med, Resp Med Unit, Solna, Sweden
[3] Karolinska Inst, Ctr Mol Med, Stockholm, Sweden
[4] Gavle Cent Hosp, Gavle, Sweden
[5] Skane Univ Hosp, Malmo, Sweden
[6] Lund Univ, Skane Univ Hosp, Dept Resp Med & Allergol, Lund, Sweden
[7] Sunderby Hosp, Lulea, Sweden
关键词
idiopathic pulmonary fibrosis; registry; quality of life; K-BILD; lung function;
D O I
10.3402/ecrj.v3.31090
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Idiopathic pulmonary fibrosis (IPF) is an emerging problem in the western world, being related to increasing age and implying significant costs for the diagnosis and management of affected patients. The epidemiology of IPF is not well understood. Methods: To allow estimates of the problem and eventually to evaluate quality of the care of IPF patients in Sweden, a national IPF Registry was started in the autumn of 2014. Data on criteria used to diagnose IPF, demographics, lung function, and quality of life (measured with the King's Brief Interstitial Lung Disease Questionnaire, K-BILD) were reported directly to the registry, based at the coordinating centre (Karolinska University Hospital, Stockholm, Sweden) via a web-based platform. Results: During the first year, the registry was implemented in 11 (33%) of the 33 respiratory units in the country. Seventy-one patients were registered between October 2014 and October 2015, 50 (70.4%) males and 21 (29.6%) females. Median age was 70 (range 47-86). The mean K-BILD score at the first inclusion in the registry was 54.3 + 9.5. Conclusions: The main features of IPF patients in this first Swedish cohort were consistent with data published in the literature in main multinational randomized controlled trials. The K-BILD questionnaire showed that quality of life of patients with IPF and their perception of the disease are quite poor at the time of inclusion in the registry.
引用
收藏
页数:6
相关论文
共 25 条
[1]  
Carlson L, 2015, LUNG ALLERGI FORUM, V3, P39
[2]   THE EPIDEMIOLOGY OF INTERSTITIAL LUNG-DISEASES [J].
COULTAS, DB ;
ZUMWALT, RE ;
BLACK, WC ;
SOBONYA, RE .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1994, 150 (04) :967-972
[3]  
Ferrara G, 2014, LUNG ALLERGI FORUM, V4, P67
[4]  
Ferrara G, 2015, LUNG ALLERGI FORUM, V4, P53
[5]  
Ferrara G, 2015, DAGENS MED, V22, P1
[6]  
Glaspole I, QUALITY LIFE PATIENT
[7]   Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK [J].
Gribbin, J. ;
Hubbard, R. B. ;
Le Jeune, I. ;
Smith, C. J. P. ;
West, J. ;
Tata, L. J. .
THORAX, 2006, 61 (11) :980-985
[8]   Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland [J].
Hodgson, U ;
Laitinen, T ;
Tukiainen, P .
THORAX, 2002, 57 (04) :338-342
[9]   Re-evaluation of diagnostic parameters is crucial for obtaining accurate data on idiopathic pulmonary fibrosis [J].
Kaunisto, Jaana ;
Kelloniemi, K. ;
Sutinen, E. ;
Hodgson, U. ;
Piilonen, A. ;
Kaarteenaho, R. ;
Makitaro, R. ;
Purokivi, M. ;
Lappi-Blanco, E. ;
Saarelainen, S. ;
Kankaanranta, H. ;
Mursu, A. ;
Kanervisto, M. ;
Salomaa, E-R. ;
Myllaerniemi, M. .
BMC PULMONARY MEDICINE, 2015, 15
[10]   A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis [J].
King, Talmadge E., Jr. ;
Bradford, Williamson Z. ;
Castro-Bernardini, Socorro ;
Fagan, Elizabeth A. ;
Glaspole, Ian ;
Glassberg, Marilyn K. ;
Gorina, Eduard ;
Hopkins, Peter M. ;
Kardatzke, David ;
Lancaster, Lisa ;
Lederer, David J. ;
Nathan, Steven D. ;
Pereira, Carlos A. ;
Sahn, Steven A. ;
Sussman, Robert ;
Swigris, Jeffrey J. ;
Noble, Paul W. .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (22) :2083-2092